Aethlon Medical Submits Biodefense Contract Proposal to U.S. Government.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has submitted a contract proposal to a Broad Agency Announcement (BAA) solicitation entitled; "Application of Platform Technologies for the Development of Therapeutic Agents for Biodefense." The solicitation (DMID-NIAID-NIHAI20080022BARDA) represents a partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the recently established Biomedical Advanced Research and Development Authority (BARDA) to award contracts that fund the development of innovative approaches to treat bioterror and emerging pandemic threats.

"We are proud of the contract response provided to NIAID and BARDA and grateful to the superb team of researchers that have agreed to participate as subcontractors in our contract proposal," stated Aethlon Chairman and CEO, James A. Joyce. The company plans to validate the Aethlon Hemopurifier[R] as a safe and innovative strategy to improve public health preparedness against bioterror and pandemic threats. Aethlon's contract response includes supporting subcontractor commitments from leading government and non-government health organizations. The United States Army Medical Research Institute for Infectious Diseases (USAMRIID), Battelle Biomedical Research Center (BMRC), The Renal Research Institute (RRI), Cato Research Institute, and The University of California Davis, School of veterinary medicine. Contract recipients will be awarded up to five years of funding directed toward activities including, research, clinical programs, and the establishment of large-scale manufacturing protocols. A significant emphasis of the contract solicitation is to aid in the development of broad-spectrum therapies able to demonstrate effectiveness against multiple bioterror pathogens and toxins.

The Hemopurifier[R] is a unique and innovative broad-spectrum treatment platform as evidenced by a breadth of supporting in vitro data and human treatment experience. The Hemopurifier[R] acts as a post-exposure therapeutic device developed to mitigate illness, suffering, and death resulting from exposure to biological weapon or emerging pandemic threats. The technology, which provides real-time clearance of circulating viruses and immunosuppressive proteins, augments the benefit of therapies procured into the strategic national stockpile (SNS) and serves as a first-line countermeasure against drug and vaccine resistant viral threats. As a broad-spectrum countermeasure, the Hemopurifier[R] diminishes the risk of treatment resistance and addresses challenges in treating naturally occurring or genetically engineered pathogens. Thus, filling voids in the armamentarium necessary to protect against existing, evolving, and future threats.

So far in 2008, the Aethlon Hemopurifier[R] has demonstrated rapid in vitro capture of H5N1 avian Influenza (Bird Flu), the reconstructed 1918 Influenza virus, West Nile virus, and Monkeypox virus, which serve as a model for human Smallpox infection. Additionally, Aethlon Medical has advanced a second human safety study of the Hemopurifier[R] in India; has executed a collaborative agreement to develop advanced filter technology for capturing high-dose chemotherapeutic agents; and has executed a license agreement that advances the filtration techniques already proven in the Hemopurifier[R] as foundation to deliver new therapies that inhibit the spread of cancer related metastases.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device designed to treat infectious disease. The Hemopurifier[R] provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier[R] is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier[R] is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier[R] in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier[R] as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier[R] in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The company has submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier[R] as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier[R] technology is available online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.